Roche's dedicated haematology testing solution, the cobas m 511 integrated haematology analyser, is now available for countries accepting the CE Mark. This launch marks the entry for Roche Diagnostics in the haematology market, with a Roche developed system.
Currently, haematology testing requires a larger blood sample from a given patient, which needs to be run across several different systems in order to get the full set of results. This is labour- and time-intensive, and potentially provides inconsistent results, as slide images are difficult to interpret.
Featuring Bloodhound technology, the cobas m 511 addresses the challenges of haematology testing by combining the three components of the process: a digital morphology analyser, cell counter and classifier into one streamlined solution which prepares, stains and analyses microscopy blood slides.
“With this launch, patients will benefit from a faster and more accurate diagnosis of blood diseases, as diverse as anemia and leukemia”, said Roland Diggelmann, chief executive officer of Roche Diagnostics. “We are entering a new area of innovation with Roche in haematology testing, supporting customers with integrated and efficient laboratory solutions, which deliver increased medical value”.
The cobas m 511 provides greater accuracy and consistency of results, compared to current technologies, by identifying, counting, isolating and categorising white blood cells, red blood cells and platelets, then presenting the digital images of all these cell types. Medical technologists can now concentrate their time on finding and classifying abnormal cells within patient samples. This automation and digitalization reduces the need for resource-intensive manual microscope reviews, supports clinicians to share challenging cases around the world and enables the delivery of quicker results, which ultimately aid patient diagnoses.
